Related Experiment Videos
Taxol (paclitaxel): future directions
1Investigational Drug Branch, National Cancer Institute, Bethesda, Maryland.
Abstract:
Paclitaxel is the first of a new class of anticancer agents with a novel mechanism of action. Demonstration of the broad activity of this drug and its unusual effects has refocused attention on tubulin as a target for anticancer drug development. Studies are under way to identify the optimal paclitaxel dose and schedule of administration and the effective combination regimens, and to exploit the drug's radiosensitizing properties. Efforts to define pharmacodynamic relationships and clinical mechanisms of resistance and to assess other potential mechanisms for the drug's anticancer activity are also under way. In addition, other compounds that target the microtubule, some more soluble and some more potent, are in various stages of development. Phase III trials in patients with ovarian, breast, and lung cancer are continuing, and adjuvant breast cancer trials will begin soon. Such trials will establish whether paclitaxel increases the cure rate and/or survival in cancer patients.
Insights
Paclitaxel, a novel anticancer agent, targets tubulin, showing broad activity. Ongoing trials investigate optimal dosing, combinations, and its potential to improve cure rates and survival in various cancers.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Paclitaxel represents a novel class of anticancer agents.
- Its unique mechanism of action targets tubulin, a key component of microtubules.
- This has revitalized interest in tubulin as a therapeutic target for cancer treatment.
Purpose of the Study:
- To summarize the current understanding and ongoing research surrounding paclitaxel.
- To highlight its broad anticancer activity and novel mechanism.
- To discuss ongoing clinical trials and future directions for paclitaxel and related microtubule-targeting agents.
Main Methods:
- Review of preclinical and clinical studies on paclitaxel.
- Analysis of ongoing Phase III clinical trials for ovarian, breast, and lung cancers.
- Exploration of research into optimal dosing, combination therapies, and radiosensitizing properties.
Main Results:
- Paclitaxel demonstrates broad anticancer activity.
- Its mechanism involves interaction with tubulin, affecting microtubule dynamics.
- Ongoing trials are evaluating its efficacy in major cancer types.
Conclusions:
- Paclitaxel is a significant anticancer drug with a unique mechanism.
- Further clinical trials are crucial to establish its role in improving patient cure rates and survival.
- Development of other microtubule-targeting agents is progressing.